Canine joint injections gain attention in OA management: full analysis

A new Clinician’s Brief podcast is putting canine therapeutic joint injections back in focus for veterinarians managing osteoarthritis and performance-related injuries. In the May 2026 episode, host Alyssa Watson, DVM, speaks with Margret Lenfest, VMD, DACVSMR, CVA, of Cornell University about the practical use of intra-articular therapy, including where it fits, what products are most commonly used, and which patients may not be appropriate candidates. (cliniciansbrief.com)

The discussion lands at a time when canine osteoarthritis care is becoming more layered and earlier intervention is getting more attention. Cornell notes that OA is chronic, progressive, and not limited to senior dogs, and that management increasingly combines weight control, rehabilitation, pain medication, and joint-directed therapies. That broader context helps explain why targeted injections are drawing interest: they offer a way to address pain and inflammation locally in dogs that may need additional relief beyond standard multimodal care, or that may not be ideal candidates for long-term systemic NSAID use. (vet.cornell.edu)

In the podcast, Lenfest identifies triamcinolone, hyaluronic acid, and platelet-rich plasma, or PRP, as the injectates most commonly used in practice. Key takeaways include starting conservatively by treating only one or two joints until the clinician understands an individual patient’s response, and recognizing clear contraindications such as infected joints, immune-mediated joint disease, cancer, compromised skin at the injection site, or inability to safely sedate the patient. She also stresses that earlier intervention tends to go better, with the aim of achieving months of benefit after injection. (cliniciansbrief.com)

Additional background from Clinician’s Brief’s December 2025 review fills in the clinical picture. That article says therapeutic joint injection is a common interventional procedure meant to concentrate medication at the source of disease, potentially reducing systemic adverse effects. It also notes that adverse effects can include transient soreness, joint flare, iatrogenic tissue damage, and septic arthritis, though serious complications appear uncommon when the technique is used judiciously. The same review recommends imaging guidance when possible, citing evidence that landmark-guided shoulder injections in dogs can lack accuracy and may cause iatrogenic cartilage damage. (cliniciansbrief.com)

The evidence base remains uneven, depending on the product. A Canadian consensus guideline published in Frontiers in Veterinary Science states that PRP currently has the most published canine research among joint injectates and is the panel’s recommended choice if a joint injection is being considered. The panel also reports that pain relief from PRP may last three to 12 months, alone or with adjunctive therapies, while noting that HA and steroid injections are generally used more palliatively. At the same time, a recent systematic review of PRP in canine OA found all included studies reported pain or function improvement, but also identified substantial reporting gaps, frequent risk of bias, and inconsistent preparation methods, making definitive efficacy conclusions difficult. (frontiersin.org)

That tension, clinical enthusiasm alongside limited standardization, is likely the most important takeaway for practicing veterinarians. Joint injections may be useful tools for selected dogs, especially in referral, sports medicine, and rehabilitation settings, but they still require careful case selection, sterile technique, informed consent with pet parents, and realistic expectations about durability and repeat treatment. They’re best viewed as one component of multimodal OA management rather than a stand-alone fix. (cliniciansbrief.com)

Why it matters: For veterinary teams, the practical appeal is clear: targeted therapy may help some patients reduce systemic medication burden, bridge gaps in comfort, or improve function in joints that remain painful despite broader OA management. But the current literature also argues for restraint. Product choice, dose, frequency, joint selection, and technique are not yet standardized across canine practice, and recommendations may change as better-controlled studies emerge. That means clinics interested in adding these procedures may need to invest not just in supplies, but in training, ultrasound capability or referral pathways, and protocols for follow-up assessment. (cliniciansbrief.com)

What to watch: The next phase will likely center on better comparative studies, more objective outcome measures, and wider adoption of image-guided injection training, all of which could determine whether therapeutic joint injections move from niche expertise toward more routine canine OA care. (cliniciansbrief.com)